Understanding risk factors, screening, and treatment of postmenopausal osteoporosis

Orthopedics

Volumn 31, Issue 7, 2008, Pages 676-680

  Johnson, Nicole K ^a   Clifford, Timothy ^a   Smith, Kelly M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECLAST; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; BONE PAIN; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEMALE; FRACTURE; HOT FLUSH; HUMAN; MYALGIA; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SCREENING; SHORT SURVEY; STOMACH ULCER; TABLET FORMULATION; VERTEBRA FRACTURE;

EID: 49549106450     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20110505-09     Document Type: Short Survey

References (36)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359(9319):1761-1767.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002; 23(4):570-578.
3. Johnell O HP. What evidence is there for the prevention and screening of osteoporosis? In: WHO Regional Office for Europe. Copenhagen, Denmark; 2006.
4. Physician's Guide to Prevention and Treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation; 2003.
5. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006; (13):340-67.
6. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137(6):529-541.
7. Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005; 353(2):164-171.
8. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005; 353(6):595-603.
9. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008;148(9):637-46.
10. Actonel (risedronate) [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals; 2008.
11. Boniva (ibandronate) tablets [package insert]. Philadelphia, PA: GlaxoSmithKline; 2006.
12. Reclast (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
13. Evista (raloxifene) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.
14. Fosamax (alendronate) [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2008.
15. Fosamax plus D (alendronate sodium/cholecalciferol) [package insert]. Whitehouse Station, NJ; Merck & Co Inc; 2008.
16. Boniva (ibandronate) injection [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2007.
17. Forteo (teriparatide (rDNA origin) injection [package insert]. Indianapolis, IN: Eli Lilly and Company; 2008.
18. Actonel with calcium (risedronate sodium tablets with calcium carbonate tablets) [package insert]. Bridgewater, NJ; Sanofi-Aventis US LLC; 2008.
19. Miacalcin (calcitonin - salmon) nasal spray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2006.
20. Fortical (calcitonin - salmon) nasal spray [package insert]. Maple Grove, MN: Upsher-Smith Laboratories; 2006.
21. LexiComp online. www.lexi.com. Accessed May 16, 2008.
22. Miacalcin (calcitonin-salmon) injection [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; 2002.
23. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006; 367(9527):2010-2018.
24. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-1822.
25. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr Pract. 2007; 13(3):232-238.
26. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23(24);8580-8587.
27. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-534.
28. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109(4):267-276.
29. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148(3):197-213.
30. Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trials. Am J Med. 2000; 109(4):330-331.
31. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002; 87(8):3609-3617.
32. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Out comes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(2):637-645.
33. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-1441.
34. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006; 354(7):669-683.
35. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlle trial. JAMA. 2002; 288(3):321-333.
36. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004; 19(8):1259-1669.